Drug Trial Radar · NCT01054820
Study to Assess the Effectiveness and Safety of FLECTOR Patch for Treatment of Acute Back Strain
Last checked: Nov 20, 2026Latest source record: Aug 16, 2012 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
123
Actual
Start
Jan 2010
Primary completion
Mar 2010
Study completion Mar 2010
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Jan 22, 2010
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Although approved for minor strains, sprains and contusions, FLECTOR Patch has not been studied extensively in the setting of acute back strain. This study is being conducted as an initial step in demonstrating the benefit of FLECTOR Patch specifically for back strain. In particular, this study is expected to provide information about the amount of improvement in back strain among subjects using the FLECTOR Patch, which may then be used to inform subsequent studies.
Conditions
- Acute Back Strain
Interventions
FLECTOR® Patch (diclofenac epolamine topical patch) 1.3%Drug
One FLECTOR Patch applied to the most painful area on the subject's back every 12 hours for up to 14 days.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean Change From Baseline to End of Treatment (EOT) in Response to Modified Brief Pain Inventory (mBPI) Question 5: Average Pain Over the Last 24 HoursTime frame: Baseline, End of Treatment (last visit up to Day 15)
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.